−0.0565USD
−79.82 MUSD
973.48 M
About CytoDyn Inc.
Sector
CEO
Jacob P. Lalezari
Headquarters
Vancouver
Website
Employees (FY)
12
Founded
2002
ISIN
US23283M1018
FIGI
BBG000BYS4X7
CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CYDY is 0.1489 USD — it has increased by 1.99% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange CytoDyn Inc. stocks are traded under the ticker CYDY.
CytoDyn Inc. is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
CYDY stock is 9.22% volatile and has beta coefficient of 0.78. Check out the list of the most volatile stocks — is CytoDyn Inc. there?
CYDY earnings for the last quarter are −0.12 USD whereas the estimation was −0.05 USD which accounts for −140.00% surprise. Estimated earnings for the next quarter are −0.05 USD. See more details about CytoDyn Inc. earnings.
CytoDyn Inc. revenue for the last quarter amounts to 1.20 M USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 50.00 K USD.
Yes, you can track CytoDyn Inc. financials in yearly and quarterly reports right on TradingView.
CYDY stock has fallen by 7.52% compared to the previous week, the month change is a 13.38% fall, over the last year CytoDyn Inc. has showed a 49.53% decrease.
CYDY net income for the last quarter is −11.92 M USD, while the quarter before that showed −9.56 M USD of net income which accounts for −24.65% change. Track more CytoDyn Inc. financial stats to get the full picture.
Today CytoDyn Inc. has the market capitalization of 145.03 M, it has increased by 6.73% over the last week.
No, CYDY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYDY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CytoDyn Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 12.00 employees. See our rating of the largest employees — is CytoDyn Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CytoDyn Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CytoDyn Inc. stock shows the sell signal. See more of CytoDyn Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.